Zacks Research Weighs in on Glaukos' Q3 Earnings (NYSE:GKOS)

Key Points

• Zacks Research has reduced Glaukos' Q3 2026 earnings estimate from $0.03 to $0.02 per share and currently holds a "Hold" rating on the stock.
• Glaukos reported a quarterly loss of ($0.24) EPS, exceeding analyst expectations, with revenue of $124.12 million, reflecting a year-over-year increase of 29.7%.
• Multiple brokerages have set diverse target prices for Glaukos, with UBS Group raising its target from $125.00 to $134.00 and maintaining a "buy" rating.

Glaukos Corporation (NYSE:GKOS - Free Report) - Equities researchers at Zacks Research reduced their Q3 2026 earnings per share estimates for shares of Glaukos in a research note issued on Wednesday, August 20th. Zacks Research analyst Team now expects that the medical instruments supplier will earn $0.02 per share for the quarter, down from their prior forecast of $0.03. Zacks Research has a "Hold" rating on the stock. The consensus estimate for Glaukos' current full-year earnings is ($1.08) per share. Zacks Research also issued estimates for Glaukos' Q4 2026 earnings at $0.09 EPS, Q1 2027 earnings at $0.08 EPS, Q2 2027 earnings at $0.29 EPS and FY2027 earnings at $0.93 EPS.

Glaukos (NYSE:GKOS - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The medical instruments supplier reported ($0.24) EPS for the quarter, beating analysts' consensus estimates of ($0.26) by $0.02. Glaukos had a negative return on equity of 8.59% and a negative net margin of 21.43%.The firm had revenue of $124.12 million for the quarter, compared to analyst estimates of $115.49 million. During the same period in the prior year, the firm posted ($0.52) EPS. The company's revenue for the quarter was up 29.7% on a year-over-year basis. Glaukos has set its FY 2025 guidance at EPS.

A number of other brokerages have also commented on GKOS. Mizuho set a $130.00 price objective on Glaukos in a report on Thursday, July 31st. BTIG Research reissued a "buy" rating on shares of Glaukos in a report on Monday, July 14th. UBS Group increased their target price on Glaukos from $125.00 to $134.00 and gave the stock a "buy" rating in a report on Thursday, July 31st. Wells Fargo & Company increased their target price on Glaukos from $86.00 to $92.00 and gave the stock an "equal weight" rating in a report on Thursday, July 31st. Finally, Truist Financial reissued a "buy" rating and set a $135.00 target price (down from $140.00) on shares of Glaukos in a report on Thursday, May 1st. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $127.42.

Glaukos Stock Performance

Shares of NYSE GKOS opened at $94.2070 on Monday. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.51 and a quick ratio of 4.69. The stock's fifty day moving average price is $96.26 and its two-hundred day moving average price is $100.70. Glaukos has a one year low of $77.10 and a one year high of $163.71. The firm has a market cap of $5.40 billion, a price-to-earnings ratio of -57.10 and a beta of 0.78.

Institutional Trading of Glaukos

Large investors have recently bought and sold shares of the business. Bessemer Group Inc. boosted its stake in Glaukos by 133.9% in the first quarter. Bessemer Group Inc. now owns 276 shares of the medical instruments supplier's stock valued at $27,000 after buying an additional 158 shares in the last quarter. Whipplewood Advisors LLC boosted its stake in Glaukos by 3,957.1% in the first quarter. Whipplewood Advisors LLC now owns 284 shares of the medical instruments supplier's stock valued at $28,000 after buying an additional 277 shares in the last quarter. First Horizon Advisors Inc. boosted its stake in Glaukos by 72.9% in the first quarter. First Horizon Advisors Inc. now owns 377 shares of the medical instruments supplier's stock valued at $37,000 after buying an additional 159 shares in the last quarter. Versant Capital Management Inc boosted its stake in Glaukos by 583.9% in the first quarter. Versant Capital Management Inc now owns 383 shares of the medical instruments supplier's stock valued at $38,000 after buying an additional 327 shares in the last quarter. Finally, Park Place Capital Corp boosted its stake in shares of Glaukos by 68.4% during the second quarter. Park Place Capital Corp now owns 399 shares of the medical instruments supplier's stock valued at $41,000 after purchasing an additional 162 shares in the last quarter. 99.04% of the stock is owned by institutional investors and hedge funds.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.